Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC

计划入组 80 人 · 首次发布于 2016 年 10 月 11 日

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

计划入组 161 人 · 首次发布于 2012 年 6 月 4 日

Study on c-Met Targeted PET/CT Imaging in NSCLC

计划入组 88 人 · 首次发布于 2025 年 4 月 4 日

c-MET(Syndivia)

c-Met-0174

c-Met agonists

C & C Oxygen Company

United States

Buchanan C Michael

United States

DENVER NEPHROLOGISTS P C

United States

Pipeline Analysis Reveals 20+ Drug Candidates for c-MET+ NSCLC Treatment

Study on Telisotuzumab Vedotin Shows Promise for c-Met-Positive NSCLC Patients

Telisotuzumab Vedotin Improves Patient-Reported Outcomes in c-Met+ NSCLC